| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-02-24 | Univercell-Biosolutions (France) iPS Academia Japan (Japan) | iPSC (induced pluripotent stem cell) patent portfolio | licensing |
Licensing agreement | ||
| 2011-02-24 | OctoPlus (The Netherlands) ESBATech (Alcon-Novartis subsidiary)(Switzerland) | controlled release formulation for one of ESBATech’s proprietary biological compounds for ophthalmic applications | undisclosed ophtalmic application | development |
Ophtalmological diseases | Development agreement |
| 2011-02-22 | IOTA Pharmaceuticals (UK) KinaseDetect (Denmark) SARomics Biostructures (Sweden) | Kinomed partnership | collaboration |
Collaboration agreement | ||
| 2011-02-22 | Grifols (Spain) Novartis (Switzerland) | immunohematology instruments, assays, semi-automated pre-transfusion diagnostic products | commercialisation distribution |
Commercialisation agreement | ||
| 2011-02-22 | Pierrel Research International (Germany-Italy)Siena Biotech (Italy) | Clinical development services | development |
Neurodegenerative diseases - Cancer - Oncology | Development agreement | |
| 2011-02-22 | Pronota (Belgium) Molecuence Corporation (Japan) | protein biomarkers | stroke | R&D |
Cerebrovascular diseases | R&D agreement |
| 2011-02-21 | Sanofi Pasteur (France) International Vaccine Institute | dengue fever | collaboration |
Infectious diseases | Collaboration agreement | |
| 2011-02-18 | Faron Pharmaceuticals (Finland) Maruishi Pharmaceutical (Japan) | Traumakine-program including FP-1201 | licensing |
Cardiovascular diseases | Licensing agreement | |
| 2011-02-17 | MediGene (Germany) Pierre Fabre Medicament (France) | Veregen® ointment (made from the extract of green tea leaves - catechins) | External genital warts | licensing |
Infectious diseases - Gynecology | Licensing agreement |
| 2011-02-15 | Evotec (Germany) ChemBridge (USA) | hit identification platform | Collaboration |
Collaboration agreement | ||
| 2011-02-15 | CIT (France) Stemina Biomarker Discovery (USA) | devTOX® assay | Collaboration |
Distribution agreement | ||
| 2011-02-15 | Boehringer Ingelheim (Germany) Pfenex (USA) | Pfenex Expression Technology ™ platform | licensing |
Licensing agreement | ||
| 2011-02-15 | Invivoscribe Technologies (USA) Novartis (Switzerland) | companion diagnostic test to identify FLT3 positive acute myeloid leukemia (AML) patients for specific use in connection with midostaurin (PKC412) | FLT3 positive acute myeloid leukemia | development |
Cancer Oncology | Development agreement |
| 2011-02-15 | Grunenthal (Germany) Xention (UK) | new drugs to treat chronic pain | chronic pain | R&D |
CNS diseases | R&D agreement |
| 2011-02-11 | Jomaa Pharma (Germany) Medicines for Malaria Venture (MMV) (UK) | fosmidomycin, as a component of non-artemisinin based combination therapy (NACT), for acute Plasmodium falciparum malaria | malaria | development |
Infectious diseases - Parasitic diseases | Development agreement |
| 2011-02-09 | Boehringer Ingelheim (Germany) Elan (Ireland) | antibody-based therapeutics | undisclosed | Development |
undisclosed | Development agreement |
| 2011-02-09 | Circassia (UK) Airmid (USA) | PAP-1 | psoriasis - atopic dermatitis | development |
Autoimmune diseases - Dermatological diseases | Development agreement |
| 2011-02-07 | Medivir (Sweden) Janssen Pharmaceutica, a J&J company (USA) | drugs based on the inhibition of the dengue NS3 protease activity | dengue fever | R&D development commercialisation |
Infectious diseases | R&D agreement |
| 2011-02-07 | Debiopharm (Switzerland) Marina Biotech (USA) | RNAi-based therapy | bladder cancer | licensing |
Cancer Oncology | Licensing agreement |
| 2011-02-03 | Novasep (France) instrAction (Germany) | purification of taxane-based active pharmaceutical ingredients (APIs) and intermediates | Development |
Cancer - Oncology | Development agreement |
